These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 8993943)

  • 21. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M; Mongiellová V; Huttová D; Cibulová L; Krivosíková Z; Spustová V; Dzúrik R
    J Cardiovasc Pharmacol; 2001 Nov; 38(5):651-6. PubMed ID: 11602811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
    van Tits LJ; Smilde TJ; van Wissen S; de Graaf J; Kastelein JJ; Stalenhoef AF
    J Investig Med; 2004 Apr; 52(3):177-84. PubMed ID: 15222407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M; Fedelesova V; Mongiellova V; Cibulova L; Huttova D; Polak F; Krivosikova Z
    Bratisl Lek Listy; 1999 Aug; 100(8):449-53. PubMed ID: 10645034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Orö L
    Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
    Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
    Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ; O'Bryan-Tear CG
    Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in the low density lipoprotein subfraction profile between oral contraceptive users and controls.
    de Graaf J; Swinkels DW; Demacker PN; de Haan AF; Stalenhoef AF
    J Clin Endocrinol Metab; 1993 Jan; 76(1):197-202. PubMed ID: 8421088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
    Boquist S; Karpe F; Danell-Toverud K; Hamsten A
    Atherosclerosis; 2002 May; 162(1):163-70. PubMed ID: 11947910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
    Qin W; Infante J; Wang SR; Infante R
    Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
    Mitropoulos KA; Armitage JM; Collins R; Meade TW; Reeves BE; Wallendszus KR; Wilson SS; Lawson A; Peto R
    Eur Heart J; 1997 Feb; 18(2):235-41. PubMed ID: 9043839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype.
    Georgieva AM; van Greevenbroek MM; Krauss RM; Brouwers MC; Vermeulen VM; Robertus-Teunissen MG; van der Kallen CJ; de Bruin TW
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):744-9. PubMed ID: 14751815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
    Melenovsky V; Malik J; Wichterle D; Simek J; Pisarikova A; Skrha J; Poledne R; Stavek P; Ceska R
    Am Heart J; 2002 Oct; 144(4):E6. PubMed ID: 12360175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.
    Raslová K; Dobiásová M; Nagyová A; Fábry R; Rauchová H; Dusinská M
    Eur J Clin Pharmacol; 1998; 54(9-10):697-9. PubMed ID: 9923570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease.
    Sbarouni E; Kyriakides ZS; Kremastinos DTh
    J Am Coll Cardiol; 1998 Nov; 32(5):1244-50. PubMed ID: 9809932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
    Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J
    Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxidation resistance of LDL in hypertriglyceridaemic patients treated with ciprofibrate.
    Nagyová A; Raslová K; Ginter E
    Physiol Res; 1998; 47(3):185-90. PubMed ID: 9803483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of simvastatin on the number and composition of apoproteinB-containing lipoproteins in hypercholesterolemia: analysis of apoproteinB in each lipoprotein fraction by highly sensitive latex method.
    Ikeda Ryomoto K; Suzuki M; Tsushima M; Yamamoto A; Harano Y
    Endocr J; 1996 Oct; 43(5):469-75. PubMed ID: 8980885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.